Silence Therapeutics plc
Silence Therapeutics plc
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||
Cash And Cash Equivalents At Carrying Value | 72 | 6 | 11 | 82 | 42 | 65 | 121 | |||||
Short Term Investments | 0 | 64 | 74 | 20 | 72 | 72 | 26 | |||||
Other Assets Current | 13 | 11 | 12 | 9 | 14 | 16 | 15 | |||||
Accounts Receivable Net Current | - | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Assets Current | 94 | 103 | 119 | 134 | 149 | 170 | 187 | |||||
Property Plant And Equipment Net | 1 | 1 | 2 | 2 | 2 | 2 | 2 | |||||
Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Goodwill | 10 | 10 | 11 | 11 | 11 | 11 | 9 | |||||
Intangible Assets Net Excluding Goodwill | - | - | 0 | - | - | - | 0 | |||||
Other Intangible Assets Net | 0 | 0 | - | 0 | 0 | 0 | 0 | |||||
Other Assets Noncurrent | 0 | 0 | 0 | 0 | 4 | 4 | 4 | |||||
Assets | 106 | 115 | 131 | 147 | 165 | 185 | 203 | |||||
Liabilities Current | ||||||||||||
Contract With Customer Liability Current | 0 | 0 | -0 | -0 | -0 | -0 | -0 | |||||
Accounts Payable Other Current | -13 | -10 | -13 | -17 | -14 | -19 | -16 | |||||
Operating Lease Liability Current | -0 | -0 | -0 | -0 | 0 | -0 | -0 | |||||
Liabilities Current | -13 | -10 | -14 | -17 | -15 | -19 | -17 | |||||
Contract With Customer Liability Noncurrent | -55 | -55 | -55 | -55 | -56 | -53 | -52 | |||||
Operating Lease Liability Noncurrent | -0 | -0 | -0 | -0 | - | - | 0 | |||||
Liabilities | -68 | -66 | -69 | -73 | -71 | -73 | -69 | |||||
Stockholders Equity | ||||||||||||
Common Stock Value | -10 | -10 | -10 | -10 | -10 | -10 | -10 | |||||
Additional Paid In Capital Common Stock | -621 | -620 | -618 | -618 | -615 | -613 | -610 | |||||
Retained Earnings Accumulated Deficit | 590 | 578 | 563 | 551 | 530 | 503 | 474 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 3 | 3 | 3 | 3 | 1 | 8 | 12 | |||||
Stockholders Equity | -38 | -49 | -62 | -74 | -94 | -113 | -134 | |||||
Liabilities And Stockholders Equity | -106 | -115 | -131 | -147 | -165 | -185 | -203 | |||||
Common Stock Par Or Stated Value Per Share | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |||||
Common Stock Shares Issued | 47 | 47 | 47 | 47 | 47 | 47 | 47 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.72% | 45.90% | 58.56% | - | - | - | - | - | - | - | - | - |
| 2025 | 64.04% | 62.64% | 78.09% | -10.59% | 2.97% | 35.69% | 4.50% | -3.88% | -12.09% | -10.36% | 40.00% | 12.73% |
| 2024 | - | - | - | - | - | - | - | - | - | -24.58% | -33.47% | -7.42% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Silence Therapeutics plc (SLN) — SEC Financial Statements & Analysis
Silence Therapeutics plc (SLN) is a pharmaceutical preparations company, incorporated in X0. Silence Therapeutics plc trades on Nasdaq, OTC as: SLN, SLNCF. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Silence Therapeutics plc reported a Gross Profit Margin of 79.50% (TTM), a Debt-to-Equity ratio of -1.77x, a Price-to-Sales (P/S) ratio of 843.35x (TTM), a Price-to-Book (P/B) ratio of 13.48x (TTM), at a market cap of $518.66M. Figures below are sourced from SEC EDGAR, as-filed.
- Gross Profit Margin TTM
- 79.50%
- Debt To Equity
- -1.77x
- P/S TTM
- 843.35x
- P/B TTM
- 13.48x
- Market Cap
- $518.66M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Silence Therapeutics plc in?
Silence Therapeutics plc (SLN) operates in the Pharmaceutical Preparations industry.
What is SLN's market cap?
Silence Therapeutics plc (SLN) has a market capitalization of $518.66M as of 2026-06-30.
What exchange does SLN trade on?
Silence Therapeutics plc (SLN) trades on the Nasdaq, OTC.
Where is Silence Therapeutics plc incorporated?
Silence Therapeutics plc is incorporated in United Kingdom.